Wird geladen...
Moxetumomab pasudotox for hairy cell leukemia: preclinical development to FDA approval
Moxetumomab pasudotox (MP) is an immunotoxin that recently received US Food and Drug Administration (FDA) approval for the treatment of hairy cell leukemia (HCL) that has failed at least 2 prior lines of therapy, including a purine analog. MP is a recombinant immunotoxin that consists of an anti-CD2...
Gespeichert in:
| Veröffentlicht in: | Blood Adv |
|---|---|
| Hauptverfasser: | , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
American Society of Hematology
2019
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6784515/ https://ncbi.nlm.nih.gov/pubmed/31594764 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000507 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|